Conflict of interest: No conflict of interest to be declared.
Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers
Article first published online: 22 OCT 2013
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd
Journal of Gastroenterology and Hepatology
Volume 28, Issue 11, pages 1746–1755, November 2013
How to Cite
Xun, Y.-h., Zang, G.-q., Guo, J.-c., Yu, X.-l., Liu, H., Xiang, J., Liu, J. and Shi, J.-p. (2013), Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers. Journal of Gastroenterology and Hepatology, 28: 1746–1755. doi: 10.1111/jgh.12304
Author contributions: Yun-hao Xun, Jun-ping Shi, and Guo-qing Zang were responsible for study design and data analysis. Yun-hao Xun, Jun-ping Shi, Jian-chun Guo, and Xiu-li Yu were responsible for patient recruitment and care. Hong Liu was responsible for histological assessment and fibrosis scoring. Jing Xiang and Jing Liu were responsible for database management. All investigators participated in drafting the manuscript, and have approved the final version of the paper.
- Issue published online: 22 OCT 2013
- Article first published online: 22 OCT 2013
- Accepted manuscript online: 25 JUN 2013 08:07PM EST
- Manuscript Accepted: 28 MAY 2013
- National Natural Science Foundation of China. Grant Numbers: 81070316/H0314, 81070335/H0316
- Natural Science Foundation of Zhejiang Province. Grant Numbers: Y2091159, Y2091200
- chronic HBV carriers;
- HBeAg positive;
- non-invasive diagnosis;
- quantitative HBsAg;
- significant fibrosis
Background and Aims
The role of serum quantitative hepatitis B surface antigen (qHBsAg) in identifying hepatitis B virus (HBV) carriers with significant fibrosis is unknown. This study aims to evaluate the diagnostic value of qHBsAg for hepatic fibrosis in hepatitis B e antigen (HBeAg)-positive HBV carriers.
Consecutive biopsy-proven HBeAg-positive HBV carriers were prospectively recruited in our center from 2009 to 2011 and were randomly divided into training and validation set. Area under receiver-operator curve (AUC) was used to determine the diagnostic accuracy of simple tests for significant fibrosis (Scheuer stage, F ≥ 2).
Overall, a total of 197 eligible patients (median age 31 years; 149 males) were enrolled. The median qHBsAg was 4.20 (log10 IU/mL). Significant fibrosis was confirmed in 112 (56.9%) patients. By logistical regression analysis, qHBsAg and γ-glutamyl transpeptidase were identified as predictors for significant fibrosis in training set (n = 124). Thus, qHBsAg index and γ-glutamyl transpeptidase to qHBsAg ratio (GqHBsR) were selected for the subsequent analysis. In the training set, an AUC of 0.762, 0.826, 0.749, and 0.771 was observed for qHBsAg index, GqHBsR, FIB-4, and aspartate aminotransferase to platelet ratio index, respectively (all P < 0.05). GqHBsR yielded a higher AUC than aspartate aminotransferase to platelet ratio index and FIB-4 (both P < 0.05). Using the optimal cut-off of 7.78, GqHBsR showed a sensitivity of 78.9% and a specificity of 73.6%. About 80% of liver biopsy could be avoided in the entire cohort.
Serum qHBsAg-based simple tests, especially GqHBsR, can accurately and specifically identify significant fibrosis in treatment-naïve HBeAg-positive HBV carriers.